ALLO – Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc.ALLO
$1.44Name : Allogene Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $314,753,920.00
EPSttm : -1.22
Allogene Therapeutics, Inc.
$1.44
11.54%$0.149Float Short %
18.31
Margin Of Safety %
Put/Call OI Ratio
0.2
EPS Next Q Diff
0.03
EPS Last/This Y
0.31
EPS This/Next Y
0.04
Price
1.29
Target Price
8.15
Analyst Recom
1.36
Performance Q
-36.14
Relative Volume
0.49
Beta
0.31
Ticker: ALLO
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-05-07 | ALLO | 1.195 | 0.23 | 1.76 | 6802 |
| 2025-05-08 | ALLO | 1.175 | 0.23 | 0.10 | 6857 |
| 2025-05-09 | ALLO | 1.15 | 0.23 | 0.01 | 6864 |
| 2025-05-12 | ALLO | 1.16 | 0.23 | 0.38 | 6924 |
| 2025-05-13 | ALLO | 1.13 | 0.23 | 0.07 | 6982 |
| 2025-05-14 | ALLO | 0.9311 | 0.20 | 0.23 | 7607 |
| 2025-05-15 | ALLO | 1.09 | 0.19 | 0.04 | 7819 |
| 2025-05-16 | ALLO | 1.11 | 0.19 | 0.01 | 7844 |
| 2025-05-19 | ALLO | 1.095 | 0.27 | 0.50 | 4342 |
| 2025-05-20 | ALLO | 1.165 | 0.27 | 0.02 | 4349 |
| 2025-05-21 | ALLO | 1.115 | 0.24 | 0.00 | 4784 |
| 2025-05-22 | ALLO | 1.095 | 0.22 | 0.00 | 5059 |
| 2025-05-23 | ALLO | 1.04 | 0.22 | 0.00 | 5059 |
| 2025-05-27 | ALLO | 1.085 | 0.22 | 0.00 | 5062 |
| 2025-05-28 | ALLO | 1.12 | 0.22 | 0.04 | 5153 |
| 2025-05-29 | ALLO | 1.185 | 0.22 | 0.03 | 5163 |
| 2025-05-30 | ALLO | 1.16 | 0.22 | 0.00 | 5193 |
| 2025-06-02 | ALLO | 1.275 | 0.22 | 0.00 | 5224 |
| 2025-06-03 | ALLO | 1.356 | 0.20 | 0.38 | 5588 |
| 2025-06-04 | ALLO | 1.28 | 0.20 | 0.00 | 5608 |
| 2025-06-05 | ALLO | 1.3 | 0.20 | 0.00 | 5640 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-05-07 | ALLO | 1.20 | 20.0 | - | -1.20 |
| 2025-05-08 | ALLO | 1.17 | 20.0 | - | -1.20 |
| 2025-05-09 | ALLO | 1.16 | 20.0 | - | -1.20 |
| 2025-05-12 | ALLO | 1.17 | 20.0 | - | -1.20 |
| 2025-05-13 | ALLO | 1.12 | 22.4 | - | -1.20 |
| 2025-05-14 | ALLO | 0.94 | 22.4 | - | -1.20 |
| 2025-05-15 | ALLO | 1.09 | 22.4 | - | -1.20 |
| 2025-05-16 | ALLO | 1.12 | 22.4 | - | -1.04 |
| 2025-05-19 | ALLO | 1.09 | 16.1 | - | -1.01 |
| 2025-05-20 | ALLO | 1.17 | 17.9 | - | -1.01 |
| 2025-05-21 | ALLO | 1.11 | 17.9 | - | -1.01 |
| 2025-05-22 | ALLO | 1.09 | 17.9 | - | -1.01 |
| 2025-05-23 | ALLO | 1.05 | 17.9 | - | -1.01 |
| 2025-05-27 | ALLO | 1.08 | 17.9 | - | -1.01 |
| 2025-05-28 | ALLO | 1.12 | 17.9 | - | -1.01 |
| 2025-05-29 | ALLO | 1.18 | 17.9 | - | -1.01 |
| 2025-05-30 | ALLO | 1.17 | 17.9 | - | -1.01 |
| 2025-06-02 | ALLO | 1.27 | 17.9 | - | -1.01 |
| 2025-06-03 | ALLO | 1.35 | 17.9 | - | -1.01 |
| 2025-06-04 | ALLO | 1.28 | 17.9 | - | -1.01 |
| 2025-06-05 | ALLO | 1.29 | 17.9 | - | -1.01 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-05-07 | ALLO | -0.28 | -11.07 | 22.91 |
| 2025-05-08 | ALLO | -0.28 | -11.07 | 22.91 |
| 2025-05-09 | ALLO | -0.28 | -11.07 | 22.91 |
| 2025-05-12 | ALLO | -0.28 | -6.39 | 21.04 |
| 2025-05-13 | ALLO | -0.28 | -6.39 | 21.04 |
| 2025-05-14 | ALLO | -0.28 | -6.39 | 21.04 |
| 2025-05-15 | ALLO | -0.28 | -6.39 | 21.04 |
| 2025-05-16 | ALLO | -0.28 | -6.39 | 20.96 |
| 2025-05-19 | ALLO | -0.28 | 1.07 | 20.15 |
| 2025-05-20 | ALLO | -0.30 | 1.07 | 20.15 |
| 2025-05-21 | ALLO | -0.30 | 1.07 | 20.15 |
| 2025-05-22 | ALLO | -0.30 | 1.07 | 20.15 |
| 2025-05-23 | ALLO | -0.30 | 1.07 | 20.15 |
| 2025-05-27 | ALLO | -0.30 | 6.76 | 20.15 |
| 2025-05-28 | ALLO | -0.30 | 6.76 | 18.31 |
| 2025-05-29 | ALLO | -0.30 | 6.76 | 18.31 |
| 2025-05-30 | ALLO | -0.30 | 6.76 | 18.31 |
| 2025-06-02 | ALLO | -0.30 | 6.98 | 18.31 |
| 2025-06-03 | ALLO | -0.30 | 6.98 | 18.31 |
| 2025-06-04 | ALLO | -0.30 | 6.98 | 18.31 |
| 2025-06-05 | ALLO | -0.30 | 6.98 | 18.31 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.28
Avg. EPS Est. Current Quarter
-0.26
Avg. EPS Est. Next Quarter
-0.25
Insider Transactions
-0.3
Institutional Transactions
6.98
Beta
0.31
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
10
Growth Score
25
Sentiment Score
40
Actual DrawDown %
97.3
Max Drawdown 5-Year %
-97.9
Target Price
8.15
P/E
Forward P/E
PEG
P/S
P/B
0.73
P/Free Cash Flow
EPS
-1.23
Average EPS Est. Cur. Y
-1.01
EPS Next Y. (Est.)
-0.97
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
0.49
Return on Equity vs Sector %
-89.5
Return on Equity vs Industry %
-71.6
EPS 1 7Days Diff
EPS 1 30Days Diff
0.19
EBIT Estimation
Allogene Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 226
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma. In addition, it provides clinical-stage products, such as ALLO-501, cema-cel, ALLO-316, ALLO-329, ALLO-715, and ALLO-605; DLL3 for the treatment of small cell lung cancer; Claudin 18.2 for the treatment of gastric and pancreatic cancer; and FLT3 for the treatment of acute myeloid leukemia. The company has license and collaboration agreements with Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
stock quote shares ALLO – Allogene Therapeutics, Inc. Stock Price stock today
news today ALLO – Allogene Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ALLO – Allogene Therapeutics, Inc. yahoo finance google finance
stock history ALLO – Allogene Therapeutics, Inc. invest stock market
stock prices ALLO premarket after hours
ticker ALLO fair value insiders trading